Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS
Europace · 2024
DOI: 10.1093/europace/euae183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, 2024. Verfasst von Paulus Kirchhof und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart and Vascular Center UKE Hamburg, Martinistraße 52, Gebäude Ost 70, 20246 Hamburg, Germany. Hauptthemen laut MEDLINE: Atrial Fibrillation, Rivaroxaban, Cause of Death, Factor Xa Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer AG.
Abstract (Originalsprache)
Aims
Anticoagulation can prevent stroke and prolong lives in patients with atrial fibrillation (AF). However, anticoagulated patients with AF remain at risk of death. The aim of this study was to investigate the causes of death and factors associated with all-cause and cardiovascular death in the XANTUS population. Methods and results Causes of death occurring within a year after rivaroxaban initiation in patients in the XANTUS programme studies were adjudicated by a central adjudication committee and classified following international guidance. Baseline characteristics associated with all-cause or cardiovascular death were identified. Of 11 040 patients, 187 (1.7%) died. Almost half of these deaths were due to cardiovascular causes other than bleeding (n = 82, 43.9%), particularly heart failure (n = 38, 20.3%) and sudden or unwitnessed death (n = 24, 12.8%). Fatal stroke (n = 8, 4.3%), which was classified as a type of cardiovascular death, and fatal bleeding (n = 17, 9.1%) were less common causes of death. Independent factors associated with all-cause or cardiovascular death included age, AF type, body mass index, left ventricular ejection fraction, hospitalization at baseline, rivaroxaban dose, and anaemia.
Conclusion
The overall risk of death due to stroke or bleeding was low in XANTUS. Anticoagulated patients with AF remain at risk of death due to heart failure and sudden death. Potential interventions to reduce cardiovascular deaths in anticoagulated patients with AF require further investigation, e.g. early rhythm control therapy and AF ablation. Trial registration numbers NCT01606995, NCT01750788, NCT01800006
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, University Heart and Vascular Center UKE Hamburg, Martinistraße 52, Gebäude Ost 70, 20246 Hamburg, Germany.
- German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany.
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
- Formerly Technical University Munich, Munich, Germany.
- Department of Neurology and Stroke Centre, Paris-Diderot-Sorbonne University, Paris, France.
- Department of Medicine, McMaster University, Hamilton, ON, Canada.
ORCID-Profile: Paulus Kirchhof, Sylvia Haas, Pierre Amarenco, Miriam Bach, A John Camm
Förderung
- Bayer AG
Zitieren
APA
Kirchhof, P., Haas, S., Amarenco, P., Turpie, A. G. G., Bach, M., Lambelet, M., Hess, S., & Camm, A. J. (2024). Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS. Europace. https://doi.org/10.1093/europace/euae183
Vancouver
Kirchhof P, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, et al. Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS. Europace. 2024. doi:10.1093/europace/euae183
BibTeX
@article{Kirchhof2024,
author = {Kirchhof, Paulus and Haas, Sylvia and Amarenco, Pierre and Turpie, Alexander G G and Bach, Miriam and Lambelet, Marc and Hess, Susanne and Camm, A John},
title = {Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS},
journal = {Europace},
year = {2024},
doi = {10.1093/europace/euae183}
}
EUVIMED